Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
EWTX 
Edgewise Therapeutics Inc (EWTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: EWTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $37.5
1 Year Target Price $37.5
| 5 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 34.17% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.50B USD | Price to earnings Ratio - | 1Y Target Price 37.5 |
Price to earnings Ratio - | 1Y Target Price 37.5 | ||
Volume (30-day avg) 10 | Beta 0.27 | 52 Weeks Range 10.60 - 38.12 | Updated Date 09/13/2025 |
52 Weeks Range 10.60 - 38.12 | Updated Date 09/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.56 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.06% | Return on Equity (TTM) -27.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 910501881 | Price to Sales(TTM) - |
Enterprise Value 910501881 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.6 | Shares Outstanding 105346000 | Shares Floating 60533751 |
Shares Outstanding 105346000 | Shares Floating 60533751 | ||
Percent Insiders 0.44 | Percent Institutions 116.32 |
Upturn AI SWOT
Edgewise Therapeutics Inc
Company Overview
History and Background
Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company founded in 2017. It focuses on developing novel treatments for severe, inherited muscle disorders. The company has progressed rapidly, advancing multiple programs into clinical trials.
Core Business Areas
- Muscle Disorder Therapeutics: Edgewise is dedicated to discovering, developing, and commercializing treatments for muscle disorders, particularly Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).
Leadership and Structure
Edgewise Therapeutics Inc. is led by a team of experienced pharmaceutical executives and scientists. The organizational structure is typical of a biotech company, with departments focused on research and development, clinical operations, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- EDG-5506: EDG-5506 is a small molecule designed to protect muscle fibers from contraction-induced damage. It is currently in clinical development for DMD and BMD. Market share data is not yet applicable as it is an investigational product. Competitors include companies developing gene therapies and other disease-modifying treatments for DMD, such as Sarepta Therapeutics (SRPT) and Solid Biosciences (SLDB).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and dynamic, with a focus on innovative therapies for unmet medical needs. The market for rare disease treatments is growing, driven by increasing awareness and regulatory incentives.
Positioning
Edgewise Therapeutics Inc. is positioned as a developer of novel, small molecule therapies for muscle disorders. Its competitive advantage lies in its unique mechanism of action and its potential to address a significant unmet need in DMD and BMD.
Total Addressable Market (TAM)
The total addressable market for DMD and BMD therapies is estimated to be several billion dollars. Edgewise Therapeutics Inc. is aiming to capture a significant share of this market with EDG-5506.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action
- Strong preclinical and clinical data
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited commercial infrastructure
- Dependence on clinical trial success
- Early stage company
- No currently approved products
Opportunities
- Positive clinical trial results
- Regulatory approval of EDG-5506
- Expansion into other muscle disorders
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Competition from other therapies
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- SRPT
- SLDB
- PTCT
Competitive Landscape
Edgewise Therapeutics Inc. faces competition from companies developing gene therapies, exon-skipping therapies, and other disease-modifying treatments for muscle disorders. Its advantages include its novel mechanism of action and its potential for oral administration.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by the advancement of its clinical programs and milestones achieved.
Future Projections: Future growth is contingent upon successful clinical trials and regulatory approvals. Analyst estimates vary based on the potential of EDG-5506 and other pipeline programs.
Recent Initiatives: Recent initiatives include the ongoing clinical trials of EDG-5506 in DMD and BMD, and exploration of new therapeutic targets in other muscle disorders.
Summary
Edgewise Therapeutics is a clinical-stage biopharma company with a promising therapy for muscle disorders. The company's future hinges on the success of EDG-5506 in clinical trials, which are progressing but carry inherent risk. Its novel mechanism is attractive, but competition in the rare disease space is intense. They need to secure strategic partnerships to grow market share faster.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Edgewise Therapeutics Inc
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2021-03-26 | President, CEO & Director Dr. Kevin Koch Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 126 | Website https://edgewisetx.com |
Full time employees 126 | Website https://edgewisetx.com | ||
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.